ClinicalTrials.gg
RecruitingNCT03908983Updated Feb 26, 2021

OPtimisation of Surgical Repair for Treating Insufficiency of the MItral Valve - Safety and Effectiveness Evaluation

An interventional study of Kalios Implant in Mitral Valve Regurgitation, sponsored by Kephalios. Recruiting at 9 sites in 4 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2021-02-26.

Sponsored by Kephalios · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2021, 5 years 5 months ago, but the record still lists the study as recruiting.
  • Started Nov 2019; still recruiting 7 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 63 studies in Mitral Valve Insufficiency with a site in Italy — 20 open to participants now, 28 under way, none of them phase 3. Mitral Valve Insufficiency · Italy.

Planned enrollment
15th of 30
100 · median 95
Started
2019
with 4 others
No phase
27 of 63
9 open now
Primary completion
2021-05
later than 3 of 27 live
Registered
30th of 63
by date

Among the 63 studies in Mitral Valve Insufficiency with a site in Italy, this one is the 15th largest by planned enrollment of the 30 interventional ones that give a count, is one of 5 that started in 2019, is one of 27 with no phase, reaches primary completion later than 3 of the 27 other live ones, and was the 30th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

20 of the 63 studies in Mitral Valve Insufficiency with a site in Italy are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Mitral Valve Insufficiency with a site in Italy, or all of them as a file.
02

Study summary

KALIOS is indicated for the surgical treatment of mitral regurgitation by mitral valve repair.It is intended for mitral valve repair using conventional open heart or minimally invasive techniques.

The KALIOS device is an adjustable annuloplasty ring, to be implanted by open surgery, having a hollow structure that comprises a flat rigid ring surrounding a deformable cage. The unique feature of KALIOS is that its annular shape and dimension can be finely adjusted percutaneously by an external actuator (three-balloon catheter) independently in the three areas corresponding to P1, P2 and P3

The primary objective of this clinical investigation is to assess the safety and effectiveness of KALIOS for the surgical treatment of Mitral Regurgitation with optional intra-operative and/or post-operative adjustment(s) The secondary objectives are to investigate the effects of KALIOS for the surgical treatment of Mitral Regurgitation on cardiac function and on patient functional status This clinical trial is prospective, non-randomized, single arm, multicentric \& international. Up to 100 patients are expected to be enrolled to obtain 62 evaluable patients at one year,presenting with primary (degenerative) or secondary (functional) mitral valve regurgitation and who are candidate to a mitral valve repair.

03

Conditions studied

  • Mitral Valve Regurgitation

Keywords

  • Mitral Regurgitation
  • Mitral valve repair
  • Mitral annuloplasty
  • Adjustable annuloplasty
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must meet ALL the following inclusion criteria :
  1. with primary or secondary mitral regurgitation recorded by TTE and confirmed during TEE where surgery for mitral valve repair is required with indications consistent with AHA/ACC and ESC/EACTS guidelines :

    1. primary (degenerative) : severe MR grade parameters (R Vol and EROA measured by PISA methods):

      • EROA regurgitant >60 ml and
      • Vena contracta width > 7mm and
      • Regurgitant fraction >50%
    2. Secondary (functional) : severe MR (EROA ≥30 mm²; R Vol > 30ml) may differ from the primary MR and are based on the prognostic value of these thresholds to predict the poor outcome, or for patients undergoing CABG
  2. with ≥ 30%
  3. in satisfactory condition, based on the physical examination and investigator's experience, with a above one year after the intervention
  4. with or without concomitant procedures as: CABG, other valve repair/replacement, pacemaker implantation, exclusion of left appendage (with device or surgically) and Maze (or PVI) procedure
  5. willing to sign the ;
  6. able and willing to comply with all clinical investigation requirements, including the required study follow-up visits

Exclusion criteria

Exclusion Criteria:

  • Patients will be excluded if ANY of the following conditions are present:

    1. of age \< 21 years;
    2. with echocardiographic measurements predicting SAM

      1. LVEDD \< 45 mm
      2. C-Sd \< 25mm (distance from the septum to the mitral valve coaptation point)
      3. Basal-IVDd > 15 mm
      4. aorto-mitral angle \< 120°
      5. pre-repair posterior leaflet height > 15 mm
    3. with cardiogenic shock;
    4. with active endocarditis (or having had active endocarditis in the last three months);
    5. with active myocarditis;
    6. with heavily calcified mitral annulus;
    7. with mitral stenosis;
    8. unable to take anticoagulation medications;
    9. with a known untreatable allergy to contrast media or nickel;
    10. with a major or progressive non-cardiac disease that, in the investigator's experience, results in a shorter than 1 year, or for whom the implant of the device produces an unacceptable increase of risk;
    11. with to transoesophageal echocardiography;
    12. with contraindication to cardiopulmonary bypass;
    13. who are pregnant or breast-feeding women;
    14. involved in any other clinical investigation for drugs or devices;
    15. unable to understand and sign the ICF in absence of legal protection;
    16. unable to read and write;
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Implanted Patients

    Implantation of Kalios Device

    Device: Kalios Implant

Interventions

  • DeviceKalios Implant

    KALIOS is an adjustable annuloplasty ring, to be implanted by open surgery, having a hollow structure that comprises a flat rigid ring surrounding a deformable cage. The unique feature of KALIOS is that its annular shape and dimension can be finely adjusted percutaneously by an external actuator (three-balloon catheter) independently in the three areas corresponding to P1, P2 and P3

06

What researchers measure

Primary outcomes

  1. Assessment of the effectiveness of KALIOS for the surgical treatment of Mitral Regurgitation with optional intra-operative and/or post-operative adjustment(s)

    Absence of Mitral Regurgitation of grade \> 2 (through echographic assessment)

    Time frame: At 1 year

  2. Assessment of the safety of KALIOS for the surgical treatment of Mitral Regurgitation with optional intra-operative and/or post-operative adjustment(s)Regurgitation with optional intra-operative and/or post-operative adjustment(s)

    Incidence of Major Adverse Cardiac Events (MACE)

    Time frame: At 1 year

Secondary outcomes

  1. Assessment of the effectiveness of KALIOS for the surgical treatment of Mitral Regurgitation with optional intra-operative and/or post-operative adjustment(s) at each follow up

    Absence of Mitral Regurgitation of grade \> 2 (through echographic assessment)

    Time frame: at 1, 3 6, 24, 36, 48 and 60 months

  2. Assessment of the adjustment functionality of the device

    Assessment of mitral leaflets coaptation (through echographic assessment)

    Time frame: immediately after annuloplasty, at 1, 3, 6, 12, 24, 36, 48 and 60 months

  3. Assessment of the adjustment functionality of the device

    Assessment of the increase of mitral leaflets coaptation length (through echographic assessment)

    Time frame: after any optional adjustment(s) performed immediately after annuloplasty, or following follow up visits at 1, 3, 6, 12, 24, 36, 48 and 60 months

  4. Assessment of the safety of KALIOS for the surgical treatment of Mitral Regurgitation with optional intra-operative and/or post-operative adjustment(s)at each follow up

    Incidence of Major Adverse Cardiac Events (MACE)

    Time frame: at 1, 3, 6, 24, 36, 48 and 60 months

07

Study locations

6 of 9 sites recruiting
  • Medical University of Vienna - Department of Surgery, Division of Cardiac Surgery
    Vienna, Austria
    Recruiting
    • Martin Andreas · Contact
  • University Clinic of Cardiac Surgery, Heart Center
    Leipzig, Germany
    Recruiting
    • Martin Misfeld · Contact
  • Klinikum Passau
    Passau, Germany
    Recruiting
    • Markus Czesla · Contact
  • Maria Cecilia Hospital Cotignola
    Cotignola, Italy
    Recruiting
    • Alberto Albertini · Contact
  • Careggi Hospital
    Florence, 50134, Italy
    Recruiting
    • Pierluigi Stefano · Contact
  • Humanitas Research Hospital
    Milan, Italy
    Not yet recruiting
    • Lucia Torraca · Contact
  • Ospedale Luigi Sacco
    Milan, Italy
    Not yet recruiting
    • Carlo Antona · Contact
  • Maria Eleonora Hospital Palermo
    Palermo, Italy
    Recruiting
    • Khalil Fattouch · Contact
  • Centre Hospitalier Universitaire Vaudois
    Lausanne, Switzerland
    Not yet recruiting
    • Matthias Kirsch · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2019 (actual). Primary completion is estimated for May 2021, 18 months after the start.

Of 91 industry-sponsored interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 144. This study's planned 18 months is below that.

Counting every sponsor, half of 144 studies reached it within 56 months; a quarter within 25 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2019
First posted
Apr 9, 2019
StartActual
Nov 20, 2019
Primary completionEst.
May 31, 2021
CompletionEst.
May 31, 2025
Last update
Feb 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03908983
Lead sponsor
Kephalios
Responsible party
Sponsor
First posted
Apr 9, 2019
Start date
Nov 20, 2019
Primary completion
May 31, 2021 (estimated)
Completion
May 31, 2025 (estimated)
Last update
Feb 26, 2021

Study contacts

Michel Finance
Contact
michel.finance@affluentmedical.com
+33 6 18 39 93 93

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion